Bausch + Lomb sees 5% organic sales growth in Q1 as IPO wraps up

Bausch Health

Bausch Health sold 35 million common Bausch + Lomb shares, or a 10.0 percent stake, at a price of $18.00 per share, in an initial public offering yielding gross proceeds of $630 million and valuing its subsidiary at about $6,300 million.

To continue reading this article subscribe now

Already an Eyewear Intelligence subscriber? Sign in here.

barrier_image_OIC

Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to ewintelligence.com - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

To continue reading this article register now.